(Q30397897)

21 June 2017

title

Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients (English)

1 reference

21 June 2017

0 references

1 reference

12

Guy Boivin

1 reference

21 June 2017

Cécile L Tremblay

1

1 reference

21 June 2017

Danielle Rouleau

2

1 reference

21 June 2017

Claude Fortin

3

1 reference

21 June 2017

Emil Toma

4

1 reference

21 June 2017

Mohamed Sylla

5

1 reference

21 June 2017

Lise Cyr

6

1 reference

21 June 2017

Serge Cote

7

1 reference

21 June 2017

Mariana Baz

8

1 reference

21 June 2017

John Sampalis

9

1 reference

21 June 2017

Lydie Trautman

10

1 reference

21 June 2017

Rafick-Pierre Sékaly

11

1 reference

21 June 2017

language of work or name

English

0 references

publication date

23 December 2010

1 reference

21 June 2017

1 reference

21 June 2017

volume

29

1 reference

21 June 2017

issue

7

1 reference

21 June 2017

page(s)

1359-1363

1 reference

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

High mortality from respiratory failure secondary to swine-origin influenza A (H1N1) in South Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Antibody Responses After Influenza and Pneumococcal Immunization in HIV-Infected Homosexual Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Influenza vaccination of HIV-1-positive and hiv-1-negative former intravenous drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Antibody response to tetravalent influenza subunit vaccine in patients infected with human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Immunogenicity of influenza vaccine (1993–1994 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

CDC advisory committee recommends nearly universal influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Responses to 2009 H1N1 vaccine in children 3 to 17 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Comparison of the effects of acute influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Vaxfectin-adjuvanted seasonal influenza protein vaccine: correlation of systemic and local immunological markers with formulation parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Response to a monovalent 2009 influenza A (H1N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

A novel influenza A (H1N1) vaccine in various age groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Safety and immunogenicity of influenza vaccination in individuals infected with HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Humoral and Cellular Response to Influenza Vaccine in HIV-Infected Children With Full Viroimmunologic Response to Antiretroviral Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Influenza immunization for HIV-infected persons in Los Angeles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Influenza immunization of HIV-1-infected patients does not increase HIV-1 viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Blunted humoral response to influenza vaccination in patients exposed to zidovudine plus trimethoprim-sulfamethoxazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Re: Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Vaccine immunogenicity in injecting drug users: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Comparative epidemiology of pandemic and seasonal influenza A in households

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.023

10.1016/J.VACCINE.2010.12.023

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference